Review on Solid lipid nanoparticles
Keywords:
Solid lipid nanoparticles, colloidal drug carriers, hydrophilic, lipophilic, homogenizationAbstract
Noble drug administration and traditional drug distribution have both failed to enhance medication bioavailability and mitigate drug toxicity. In recent years, tailored drug delivery systems have become significant for administering medications with less toxicity and enhanced bioavailability. Nanotechnology has revolutionized medicinal delivery. Solid lipid nanoparticles (SLNs) have demonstrated efficacy as superior medication carriers. SLNs possess several uses in the prevention of cancer and tuberculosis, and they serve as adjuvants in different vaccinations. The preparation procedures for solid lipid nanoparticles (SLNs) encompass homogenization under pressure, ultrasonication, and solvent evaporation, and are contingent upon the characteristics of the medication. The biodistribution of pharmaceuticals is a difficulty, effectively addressed by selecting the optimal route of administration. The characterization of drugs is crucial for solid lipid nanoparticles (SLNs) to enhance drug bioavailability, encompassing several techniques such as electron microscopy, particle size analysis, and zeta potential measurement.
Downloads
Metrics
References
Pavankumar AR, Parthiban S (2014) A modern review on solid lipid nanoparticles as novel controlled drug delivery system. Ijrpns 3(4): 313-325.
C. Shah, V. Shah, U. Upadhyay, solid lipid nanoparticles: a review current pharma research, 1(4), 2011, 351-368.
R. Cavalli, M. R. Gasco, P. Chetoni, S. Burgalassi, Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. International Journal Pharm, 238, 2002, 241 – 245.
N. K. Jain, Controlled and Novel Drug Delivery 1st Edition, (CBS Publishers and Distributors1997) 3-28.
Rivastigmine Tartrate Solid Lipid Nanoparticles Loaded Transdermal Film: An In vivo study, Ravi G, Vishal Gupta N, Balamuralidhara V, Vol-11, Pag 227-230, 2018, RJPT.
S.A. Wissing, R.H. Muller, Solid lipid nanoparticles (SLN) a novel carrier for U V blockers. Pharmazie 56, 2001, 783-786. C. Rudolph, U. Schillinger, A. Ortiz, K. Tabatt, C. Plank, R.H. Muller, Application of novel Solid lipid nanoparticles (SLN) - gene vector formulations based on a diametric HIV-1 VAT - peptide in vitro and in vivo.Pharmaceutic Res, 21, 2004, 1662-1669.
Effect of Lipids and Surfactants on Solid Lipid Nanoparticle Engineering, Baviskar Anagha, Hiremath Shivanand, Akul Manoj, Pawar Poonam, Vol- 4, Pag-521-526, 2011, RJPT.
P. Rabinarayan, S. Padilama, Production of Solid Lipid Nanoparticles-Drug Loading and Release Mechanism. Journal of Chemical and Pharmaceutical Research, 2(1), 2010, 211-227.
B. Siekmann, K. Westesen. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. European J. Pharm. Biopharm, 43, 1996, 104-109.
S.H. Gohla, A. Dingler, Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie, 56, 2001, 61-63.
C. Schwarz, W. Mehnert, J.S. Lucks, R.H. Müller, Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. Journal of Controlled Relelease, 30, 1994, 83-96.
F. Lai, S.A. Wissing, R.H. Muller, A. M. FaddaArtemisia arborescensL essential oil-loaded solid lipid nanoparticles for potential agriculture application: Preparation and characterization. AAPS Pharm Sci Tech, 7, 2006, 21-27.
R.Pandey, S. Sharma, G.K. Khuller. Oral SLN Based antitubercular chemotherapy, Tuberculosis (Edinb) 85, 2005, 415-420.
Formulation, Characterization and Applications on Solid Lipid Nanoparticles – A Review., S. Harshavardhan Reddy, M. S. Umashankar, N. Damodharan., Vol- 11, Pag-5691-5700, 2018, RJPT.
Solid Lipid Nanoparticles – Preparation, Applications, Characterization, Uses in Various Cancer Therapies, Sachin J., N. Vishal Gupta., Vol-6, Pag-825-837, 2013. Research Journal of Pharmaceutics and Technology.
K. Ruckmani, M. Sivakumar, P.A. Ganeshkumar, Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. Journal Nano sciences Nanotechnology, 6, 2006, 2991-2995.
R. Cortesi, E. Esposito, G. Luca, C.Nastruzzi.Production of lipospheres as carriers for bioactive compounds.Biomaterials, 23, 2002, 2283-2294.
S.C.Yang, L.F.Lu, Y. Cai, J.B. Zhu, B.W. Liang, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. Journal of Control Release, 59, 1999, 299-307.
S. Pragati, S. Kuldeep, S. Ashok, Solid Lipid Nanoparticles: A Promising Drug Delivery Technology. International Journal of Pharmaceutical Sciences and Nanotechnology, 2(2), 2009, 509-516.
S. N. Mistry, P. K. Patel, P. D. Bharadia, V. M. Pandya, D. A. Modi, Novel Drug Delivery System for Lipophilic Agents: Solid Lipid Nanoparticles. IJPI’s Journal of Pharmaceutics and Cosmetology 1(4), 2011, 76-89.
Voriconazole Solid Lipid Nanoparticles: Optimization of Formulation and Process Parameters , Srikar Grandhi*, A. Prameela Rani, Raghuveer Pathuri, Vol- 11, 2018.
F. Lai, S.A. Wissing, R.H. Muller, A. M. FaddaArtemisia arborescensL essential oil-loaded solid lipid nanoparticles for potential agriculture application: Preparation and characterization. AAPS Pharm Sci Tech, 7, 2006, 21-27.
Formulation, Characterization and in vitro Evaluation of Methotrexate Solid Lipid Nanoparticles, Jameel Ahmed Mulla, Sarasija Suresh, Imtiyaz Ahmed Khazi, Vol-2, Pag-685-689, 2009, RJPT.
Quality by Design approach in the development of Solid Lipid Nanoparticles of Linagliptin, D. Krishna Veni, N. Vishal Gupta, Vol- 12, Pag 4454-4462, 2019, RJPT.
S. P. Vyas and R. K. Khar, Controlled Drug Delivery - Concepts and Advances, 1st Edition, (VallabhPrakashan 2002) 38-50.
P. K. Gupta, J. K. Pandit, A. Kumar and P. Swaroop, S.gupta, T. Ph. Res., 3, 2010117-138.
B. Lu, S.B. Xiong, H. Yang, X.D. Yin, R.S. Chao, Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymphnode metastases. European Journal of Pharm. Sciences, 28, 2006, 86-95.
A Review on solid Lipid Nanoparticles, D. Thulasi Ram*, Subhashis Debnath, M. Niranjan Babu, T. Chakradhar Nath, Thejeswi B. Vol-5, 2012. RJPT.
Quality by Design approach in the development of Solid Lipid Nanoparticles of Linagliptin, D. Krishna Veni, N. Vishal Gupta, Vol- 12, Pag 4454-4462, 2019, RJPT.
M.C. Santos, W. Mehnert, M. Schaller, Drug targeting by solid lipid nanoparticles for dermal use. Journal Drug Target, 10, 2002, 489-495.
Isotretinoin-Loaded Solid-Lipid Nanoparticles: A Sound Strategy for Skin Targeting, Surbhi Sharma*, M.S. Ashawat and N.S. Solanki, Vol- 5, 2011, RJPT.
H. Chen, X. Chang, D. Du, W. Liu, J. Liu, Podophyllotoxin- loaded solid lipid nanoparticles for epidermal targeting. Journal of Control Release 110, 2006, 296-306.
V. Jenning, S. Gohla, Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. Journal of Control Release, 66, 2000, 115-126.
F. Lai, S.A. Wissing, R.H. Muller, A. M. FaddaArtemisia arborescensL essential oil-loaded solid lipid nanoparticles for potential agriculture application: Preparation and characterization. AAPS Pharm Sci Tech, 7, 2006, 21-27.
Y. Wang, W. Wu, In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Delivery, 13, 2006, 189-192.
Formulation and Evaluation of Glyceryl Behenate based Solid Lipid Nanoparticles for the delivery of Donepezil to brain through Nasal Route, Mohd Yasir, Iti Chauhan, Misbahu J. Haji, Abdurazak J. Tural, Prasoon K. Saxena, Vol-11, Pag 2836-2844. 2018. RJPT
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
